 Navigating the Spectrum of Fibrotic Lung Disease–From Idiopathic Pulmonary Fibrosis (IPF) to Progressive Pulmonary Fibrosis (PPF) | |
| 主辦單位 | 社團法人高雄縣醫師公會 |
| 協辦單位 | 財團法人私立高雄醫學大學附設高醫岡山醫院 |
| 協辦廠商 | |
| 日期時間 | 115年2月13日（五）12:30-14:30 |
| 課程地點 | 財團法人私立高雄醫學大學附設高醫岡山醫院3樓大講堂（高雄市岡山區捷安路8號） |
| 報名截止日期 | 請逕自至現場聆聽（餐點數量有限，請欲上課會員準時至現場上課） |
| 講師 | 蔡英明／財團法人私立高雄醫學大學附設高醫岡山醫院胸腔內科 |
| 課程簡介 | Background: Interstitial lung diseases (ILDs) comprise a diverse group of disorders characterized by varying degrees of inflammation and fibrosis. Historically, Idiopathic Pulmonary Fibrosis (IPF) has been recognized as the most common and lethal form of progressive fibrosing ILD. However, recent clinical observations have identified a subset of patients with non-IPF ILDs—such as chronic hypersensitivity pneumonitis or autoimmune-related ILDs—who exhibit a clinical phenotype similar to IPF, characterized by self-sustaining, worsening lung scarring. This phenomenon is now formally classified as Progressive Pulmonary Fibrosis (PPF). Objective: This abstract explores the diagnostic transition from a purely etiology-based approach to a behavior-based approach, emphasizing the shared physiological decline between IPF and the broader PPF umbrella. Methodology & Criteria: While IPF is defined by a specific radiologic or histologic pattern of Usual Interstitial Pneumonia (UIP) in the absence of a known cause, PPF is defined by evidence of disease progression despite conventional treatment. Current clinical guidelines define PPF through a combination of three criteria within a 12-month period with worsening respiratory symptoms, pohysiological decline (absolute 5% decline in FVC or a 10% decline in DLCO, and radiological evidence of increased fibrosis on high-resolution computed tomography (HRCT). Results & Conclusion: The recognition of PPF has revolutionized treatment paradigms. Clinical trials (such as INBUILD) have demonstrated that antifibrotic therapies, originally approved for IPF, are also effective in slowing the rate of FVC decline in patients with other progressive fibrotic phenotypes. Consequently, the distinction between IPF and PPF is no longer just academic; it is vital for early therapeutic intervention. Transitioning to a “unified fibrotic phenotype” model allows for more aggressive management of non-IPF patients, potentially extending survival and improving quality of life across the spectrum of fibrotic lung disease. |
| 申請積分 | 中華民國醫師公會全國聯合會-專業課程、 家醫科、內科申請中 |
| 備註 | *參加實體課程者，課程學分簽到會使用QR code線上簽到、簽退方式，請務必攜帶手機 *請配合醫療院所相關防疫規定 醫事人員執業登記及繼續教育辦法 醫事人員執業，應接受下列課程之繼續教育： A專業課程 B專業品質 C專業倫理 D專業相關法規 A+ B+C+D合計一百二十點，其中B+C+D 至少十二點（應包括感染管制及性別議題之課程）；超過二十四點者，以二十四點計 KaoHsiung Kcma 社團法人高雄縣醫師公會 |